This site is intended for US Population-Health Decision Makers or similar entities at hospitals and US oncology practices.
The Multifaceted Impact of Thrombotic Events in PV
IMPACT ON
PATIENTS
HIGHER RISK OF TEs IN PV1
In a population-based
study* of 9429 patients
with MPNs, including
3001 with PV
In a population-based study* of 9429 patients
with MPNs, including 3001 with PV
4.2x
risk of thrombosis
in patients with PV
vs matched controls
4.2x
risk of thrombosis
in patients with PV vs matched controls HR, 4.2; CI, 3.5–5.0
*Population-based study based on Swedish Cancer Registry data for 1987-2009 in 9429 patients with MPNs. 9429 MPN patients (PV=3001, ET=3462, PMF=1488, and MPN-U=1478) and 35,820 matched controls were identified and included in the study. Hazard ratio for thrombosis at 3 months post-diagnosis was 4.2 for PV (95% CI, 3.5–5.0) vs
4.0 for all MPNs (95% CI, 3.6–4.4).1
CI=confidence interval; ET=essential
thrombocythemia; HR=hazard ratio;
MPN=myeloproliferative neoplasm;
MPN-U=myeloproliferative neoplasm unclassifiable;
PMF=primary myelofibrosis; PV=polycythemia vera;
TEs=thrombotic events.
thrombocythemia; HR=hazard ratio;
MPN=myeloproliferative neoplasm;
MPN-U=myeloproliferative neoplasm unclassifiable;
PMF=primary myelofibrosis; PV=polycythemia vera;
TEs=thrombotic events.
Consider
Quality
Initiatives
for patients with advanced PV who are at risk of a thrombotic event
- Manage appropriate blood counts
- Monitor disease-related symptoms
- Optimize dosing
IMPACT ON THE
HEALTHCARE SYSTEM
A retrospective
cross-sectional analysis*
of US healthcare resource
utilization and costs
for adult patients with
PV and TEs demonstrated
A retrospective cross-sectional analysis*
of US healthcare resource utilization and costs
for adult patients with PV and TEs demonstrated
Patients with TEs
demand greater
healthcare
resources vs those
without TEs7
3x the cost of healthcare7
3x the cost of healthcare7$45,040 mean total
annual costs for patients
with PV and TEs vs
$16,438 for those
without TEs (P < 0.001)
$45,040 mean total annual costs for patients with PV and TEs vs $16,438 for those without TEs (P < 0.001)
*Retrospective cross-sectional database analysis including 1322 adult patients with a PV diagnosis who were newly treated with hydroxyurea and continuously enrolled in medical and pharmacy benefit plans for
≥12 months pre- and post-index. Healthcare resource utilization and costs were analyzed in a subgroup analysis comparing patients who had TEs in the 12-month follow-up period with those who did not.7
Consider
Quality
Initiatives
for patients with advanced PV who are at risk of a thrombotic event
- Manage appropriate blood counts
- Monitor disease-related symptoms
- Optimize dosing